Laws and Labels: A Regulatory View of Biosimilars

Friday, October 30, 2015
Presented by: 
Erika Lietzan

Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.

You may also like:

Blog Post

By now, we’ve all heard: Measles is back. As of May 31, 2019, 7,981 cases of measles had been reported in the U.S in 26 states. Approximately...

View Blog Post
Blog Post

At the recent NCPDP Joint Technical Work Group Meetings, held in Scottsdale in early May, the membership voted to approve three emergency external code list changes. These changes are in response to the Office of the Inspector ...

View Blog Post
Blog Post

For healthcare professionals recently, it seems like nearly every patient, customer at the pharmacy counter, and friend of your mother's has questions about the same thing. CBD oil. CBD...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up